Genmab to increase share capital by 0.01% through employee warrants

COPENHAGEN - Danish biotechnology company Genmab A/S (Nasdaq:GMAB), currently valued at $13 billion and showing "GREAT" financial health according to InvestingPro analysis, announced Tuesday it will increase its share capital by 4,563 shares following the exercise of employee warrants.

The capital increase, which represents approximately 0.01% of the company’s total share capital, will be implemented without preemption rights for existing shareholders. The new shares are being subscribed in cash at varying prices: 2,580 shares at DKK 1,025.00, 1,874 shares at DKK 1,050.00, and 109 shares at DKK 1,161.00. With impressive gross profit margins of 94.5% and more cash than debt on its balance sheet, Genmab demonstrates robust financial fundamentals.

The transaction will generate proceeds of approximately DKK 4.7 million for Genmab. The company stated that the newly issued shares will be ordinary shares without special rights and will be freely transferable negotiable instruments.

Following the capital increase, Genmab’s total share capital will consist of 64,158,817 shares with a nominal value of DKK 1 each, corresponding to 64,158,817 votes. The new shares will provide rights to dividends and other company benefits from the time of subscription.

The company expects the new shares to be listed on Nasdaq Copenhagen after registration with the Danish Business Authority, with the capital increase finalized shortly.

Genmab, established in 1999, focuses on developing antibody therapeutics for cancer and other serious diseases. According to InvestingPro analysis, the company appears undervalued at its current trading price, with multiple positive indicators suggesting strong growth potential. The announcement was made in a company press release issued Tuesday. Get access to 10 more exclusive ProTips and comprehensive analysis through InvestingPro’s detailed research reports.

In other recent news, Genmab AS reported strong financial results for the second quarter of 2025, significantly exceeding earnings expectations. The company announced an earnings per share (EPS) of $0.542, which represents a 39.4% increase over the forecast of $0.3888. Additionally, Genmab achieved revenue of $925 million, surpassing predictions by 3.54%. These results highlight the company’s robust financial performance during the period. While the stock saw a notable increase of 5.49% following the announcement, premarket trading indicated a slight decline. These developments reflect the company’s current financial health and position in the market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.